TLR4 and neoplasm: Several studies have shown that chemotherapy can activate toll-like receptor 4 (TLR4) receptors on macrophages, further activating immune responses, while other studies have shown that chemotherapy drugs can remodel tumor cell immunogenicity through the regulation of major histocompatibility class I (MHC I) expression, enhancing tumor antigen presentation (39–41).